It’s been five years since the first CAR T-cell therapy was approved, marking the beginning of a new era in cancer therapy, but it’s been a huge effort from pharma to turn them into commercial therapies. David Sourdive, co-founder and vice president for CMC and manufacturing at gene and cell therapy specialist Cellectis SA, is one of many in the field of advanced therapies who argue that CAR T cells are just the vanguard from a new army of cell therapies that could prove decisive in the war against cancer.